Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Anders Mellemgaard, Ghada F. Ahmed, Xiaoling Ou, Geoffrey R. Oxnard, Kiyotaka Yoh, Toyoaki Hida, Yuichiro Ohe, Hideo Saka, Manabu Hayama, Tomonori Hirashima, Ko Sugibayashi, Takayasu Kurata, Remy B. Verheijen
Publikováno v:
Targeted Oncology
Background Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome
Autor:
Satoshi Nomura, Keisuke Aoe, Makoto Nishio, Toyoaki Hida, Takeshi Tajima, Kadoaki Ohashi, Takashi Seto, Masayuki Takeda, Sanae Moizumi, Shunichi Sugawara
Publikováno v:
Cancer Science
MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable saf
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Takumi Kishimoto, Yutaro Kaneko, Toyoaki Hida, Yuichiro Ohe, Masayuki Takeda, Masayuki Yamada, Kazuhiko Nakagawa, Chikao Morimoto, Hidehito Horinouchi, Junichi Shimizu, Takashi Seto, Itaru Miyashita, Kaname Nosaki
Publikováno v:
Lung Cancer. 137:64-70
Objectives CD26 is a transmembrane glycoprotein with dipeptidyl peptidase IV activity that is overexpressed in malignant pleural mesothelioma (MPM). We performed a phase I study to determine the maximum tolerated dose, pharmacokinetics, and antitumor
Autor:
Junichi Shimizu, Waki Hosoda, Toyoaki Hida, Takeo Nakada, Takuya Matsui, Keita Nakanishi, Noriaki Sakakura, Harushi Ueno, Hiroaki Kuroda, Yuko Oya
Publikováno v:
Anticancer Research. 39:5789-5795
Background/aim Pulmonary pleomorphic carcinoma (PPC) is rare, and few studies have reported its features. We assessed the clinicopathological features, surgical outcomes, oncogenic status and programmed death-ligand 1 (PD-L1) expression of PPC. Patie
Autor:
Takashi Kijima, Hiroshi Tanaka, Kazuhiko Nakagawa, Keisuke Aoe, Mitsuhiro Takenoyama, Morihito Okada, Toshiaki Takahashi, Yuichiro Ohe, Yuichiro Takeda, Toyoaki Hida, Terufumi Kato, Yoshinobu Namba, Fumio Imamura, Satoshi Oizumi, Jun Hirano, Kuninobu Kanai, Nobukazu Fujimoto
Publikováno v:
Clinical Cancer Research. 25:5485-5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of ni
Autor:
Koichi Goto, Mitsuhiro Takenoyama, Koji Takeda, Shinji Atagi, Hidehito Horinouchi, M. Nishio, Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Tomonori Hirashima, Hideo Saka, Naoki Sumiyoshi, Hiroshi Isobe, Hiroshi Sakai, Miyako Satouchi, Toyoaki Hida, Toshiaki Takahashi, Hiroshi Tanaka, Koichi Minato, Makoto Maemondo, Nobuyuki Katakami
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previo
Autor:
Hiroshi Tanaka, Toyoaki Hida, Keiji Nihei, Yuichiro Ohe, Tetsuo Akimoto, Shigeki Umemura, Koichi Goto, Yukio Hosomi, Hiroaki Okamoto, Seiji Niho
Publikováno v:
Japanese Journal of Clinical Oncology. 49:614-619
Objectives We conducted a Phase I/II study of carboplatin, S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients (71 years or older) with unresectable stage III non-small cell lung cancer (NSCLC). Materials and methods Patients received
Autor:
Junichi Shimizu, Teppei Yamaguchi, Takaaki Hasegawa, Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Yoshitaka Inaba
Publikováno v:
Lung Cancer. 125:212-217
Objectives Pneumonitis related to the use of anti-programmed death 1 (PD-1) antibodies is a common immune-related adverse event that can be life-threatening. However, the relationship between pulmonary fibrosis/emphysema and the incidence of anti-PD-